BMF-650 — Topline data
Q3 2026
Our Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers is ongoing, with topline results expected in the third quarter of 2026.Source filing
BMEA biotech catalysts & pipeline
BIOMEA FUSION INC · Data as of 2026-09-08
Upcoming catalysts
icovamenib — Topline data
Q4 2026
Both trials include a 26-week primary endpoint, with topline data anticipated in the fourth quarter of 2026.Source filing
icovamenib — Topline data
Q1 2027
Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes ("T2D"); data expected in the first quarter of 2027Source filing
icovamenib — Topline data
Q2 2027
Enrollment also ongoing for the Phase II COVALENT-212 clinical trial in patients with T2D not achieving glycemic targets while on glucagon-like peptide-1 receptor agonists ("GLP-1 RA")-based therapy; data expected in the second quarter of 2027Source filing